AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

IMPEDIMED LTD

0.034

+0.0013.03%

Volume:3.25M

Turnover:111.87K

Market Cap:68.87M

PE:-5.61

High:0.035

Open:0.033

Low:0.033

Close:0.033

Loading ...

Overview Company News Filings

ImpediMed Anticipates No Material Impact From U.S. Tariffs-Ipd.ax

THOMSON REUTERS

ImpediMed Ltd - ImpediMed Anticipates No Material Impact From U.S. Tariffs

THOMSON REUTERS

BRIEF-ImpediMed Ltd Says HY Revenue From Ordinary Activities A$6.0 Million

ImpediMed - FY Net Loss Attributable a$11.1 Mln

THOMSON REUTERS

ImpediMed Ltd - Hy Revenue From Ordinary Activities a$6.0 Mln

THOMSON REUTERS

ImpediMed Unit Secures $15 Million Growth Capital Facility; Shares Rise 3%

MT Newswires Live

BRIEF-ImpediMed Ltd Says Secured $15 Million Growth Capital Facility

BUZZ-Australia's ImpediMed gains on five-year $15 million growth capital facility

ImpediMed - Unit Executed Agreement for a 5-Year Growth Capital Facility With SWK Funding

THOMSON REUTERS

ImpediMed Ltd - Secures US$15 Mln Growth Capital Facility

THOMSON REUTERS

ImpediMed (ASX:IPD) investors are sitting on a loss of 72% if they invested three years ago

Simply Wall St.

The ASX medtech innovator positioned for growth

3 ASX Penny Stocks With Market Caps Larger Than A$30M

Simply Wall St.

We Think ImpediMed (ASX:IPD) Needs To Drive Business Growth Carefully

Simply Wall St.

The ASX stocks the big brokers loved and hated this week

BRIEF-Impedimed POsts Unaudited Revenue Of A$2.7 Million For Quarter

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/IPD.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IPD.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IPD.AU\",,,,,undefined,":{"symbol":"IPD.AU","market":"AU","secType":"STK","nameCN":"IMPEDIMED LTD","latestPrice":0.034,"timestamp":1745302320000,"preClose":0.033,"halted":0,"volume":3246555,"delay":0,"nameEN":"IMPEDIMED LTD","floatShares":1830611600,"shares":2025728336,"eps":-0.006059,"marketStatus":"Closed","change":0.001,"latestTime":"04-22 16:12:00 AEST","open":0.033,"high":0.035,"low":0.033,"amount":111867,"amplitude":0.060606,"askPrice":0.035,"askSize":176243,"bidPrice":0.034,"bidSize":613738,"shortable":3,"etf":0,"ttmEps":-0.006059,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1745366400000},"marketStatusCode":5,"adr":0,"exchange":"ASX","adjPreClose":0.033,"openAndCloseTimeList":[[1745280000000,1745301600000]],"volumeRatio":2.541445,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IPD.AU\",,,,,undefined,":{"symbol":"IPD.AU","floatShares":1830611600,"roa":"-29.71%","roe":"-50.94%","lyrEps":-0.009788,"volumeRatio":2.541445,"shares":2025728336,"dividePrice":0,"high":0.035,"amplitude":0.060606,"preClose":0.033,"low":0.033,"week52Low":0.032,"pbRate":"2.13","psRate":"5.97","week52High":0.102,"institutionHeld":0,"latestPrice":0.034,"committee":0.553804,"eps":-0.006059,"divideRate":0,"volume":3246555,"delay":0,"ttmEps":-0.006059,"open":0.033,"prevYearClose":0.052,"prevWeekClose":0.033,"prevMonthClose":0.041,"prevQuarterClose":0.041,"fiveDayClose":0.036,"twentyDayClose":0.043,"sixtyDayClose":0.055,"earningDate":1745942400000},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IPD.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2526801656","title":"ImpediMed Anticipates No Material Impact From U.S. Tariffs-Ipd.ax","url":"https://stock-news.laohu8.com/highlight/detail?id=2526801656","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526801656?lang=en_us&edition=fundamental","pubTime":"2025-04-09 11:48","pubTimestamp":1744170491,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250409:nFWN3QM1Z2:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7007","BK7509","IPD.AU"],"gpt_icon":0},{"id":"2526380165","title":"ImpediMed Ltd - ImpediMed Anticipates No Material Impact From U.S. Tariffs","url":"https://stock-news.laohu8.com/highlight/detail?id=2526380165","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526380165?lang=en_us&edition=fundamental","pubTime":"2025-04-09 11:48","pubTimestamp":1744170491,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250409:nFWN3QM1Z2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IPD.AU","BK7007","BK7509"],"gpt_icon":0},{"id":"2514246300","title":"BRIEF-ImpediMed Ltd Says HY Revenue From Ordinary Activities A$6.0 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2514246300","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514246300?lang=en_us&edition=fundamental","pubTime":"2025-02-26 09:12","pubTimestamp":1740532354,"startTime":"0","endTime":"0","summary":"BRIEF-ImpediMed Ltd Says HY Revenue From Ordinary Activities A$6.0 MillionFeb 26 (Reuters) - ImpediMed Ltd IPD.AX:HY REVENUE FROM ORDINARY ACTIVITIES A$6.0 MILLIONFY NET LOSS ATTRIBUTABLE A$11.1 MILLIONFurther company coverage: IPD.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250226:nFWN3PG0M6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IPD.AU"],"gpt_icon":0},{"id":"2514041698","title":"ImpediMed -  FY Net Loss Attributable a$11.1 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2514041698","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514041698?lang=en_us&edition=fundamental","pubTime":"2025-02-26 05:12","pubTimestamp":1740517936,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250225:nFWN3PG0M6:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IPD.AU","BK7007","BK7509"],"gpt_icon":0},{"id":"2514041662","title":"ImpediMed Ltd - Hy Revenue From Ordinary Activities a$6.0 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2514041662","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514041662?lang=en_us&edition=fundamental","pubTime":"2025-02-26 05:12","pubTimestamp":1740517936,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250225:nFWN3PG0M6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7509","IPD.AU","BK7007"],"gpt_icon":0},{"id":"2509951812","title":"ImpediMed Unit Secures $15 Million Growth Capital Facility; Shares Rise 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2509951812","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509951812?lang=en_us&edition=fundamental","pubTime":"2025-02-06 10:39","pubTimestamp":1738809561,"startTime":"0","endTime":"0","summary":"ImpediMed  subsidiary, ImpediMed, secured a five-year $15 million growth capital facility with US-based specialist finance company SWK Funding, according to a Thursday filing with the Australian bourse.The facility will be used for growth and commercialization activities, with $10 million available immediately in tranche one and $5 million available in tranche two if the company meets sales targets for the current fiscal year and decides to draw on the facility, the filing said.ImpediMed shares rose 3% in afternoon trade Thursday.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IPD.AU","BK7509","BK7007"],"gpt_icon":0},{"id":"2509794260","title":"BRIEF-ImpediMed Ltd Says Secured $15 Million Growth Capital Facility","url":"https://stock-news.laohu8.com/highlight/detail?id=2509794260","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509794260?lang=en_us&edition=fundamental","pubTime":"2025-02-06 09:51","pubTimestamp":1738806709,"startTime":"0","endTime":"0","summary":"BRIEF-ImpediMed Ltd Says Secured $15 Million Growth Capital FacilityFeb 6  - ImpediMed Ltd IPD.AX:SECURES US$15 MILLION GROWTH CAPITAL FACILITYUNIT EXECUTED AGREEMENT FOR A 5-YEAR GROWTH CAPITAL FACILITY WITH SWK FUNDINGFurther company coverage: IPD.AX ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250206:nFWN3OW1ZF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IPD.AU","BK7509","BK7007"],"gpt_icon":0},{"id":"2509264978","title":"BUZZ-Australia's ImpediMed gains on five-year $15 million growth capital facility","url":"https://stock-news.laohu8.com/highlight/detail?id=2509264978","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509264978?lang=en_us&edition=fundamental","pubTime":"2025-02-06 09:00","pubTimestamp":1738803640,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's ImpediMed gains on five-year $15 million growth capital facility** Shares of ImpediMed IPD.AX rise 5% to A$0.0525** Stock set for best session since December 9, 2024, if gains hold** The medical technology co's unit executes an agreement for a five-year $15 million growth capital facility with SWK Funding** Co adds that funds raised will be used to support growth and commercialisation activities** Stock down 3.9% this year, as of last close  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250206:nL4N3OX02L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IPD.AU","BK7007","BK7509"],"gpt_icon":0},{"id":"2509257122","title":"ImpediMed - Unit Executed Agreement for a 5-Year Growth Capital Facility With SWK Funding","url":"https://stock-news.laohu8.com/highlight/detail?id=2509257122","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509257122?lang=en_us&edition=fundamental","pubTime":"2025-02-06 06:24","pubTimestamp":1738794258,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250205:nFWN3OW1ZF:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7007","IPD.AU","BK7509"],"gpt_icon":0},{"id":"2509173257","title":"ImpediMed Ltd - Secures US$15 Mln Growth Capital Facility","url":"https://stock-news.laohu8.com/highlight/detail?id=2509173257","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509173257?lang=en_us&edition=fundamental","pubTime":"2025-02-06 06:24","pubTimestamp":1738794258,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250205:nFWN3OW1ZF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7007","IPD.AU","BK7509"],"gpt_icon":0},{"id":"2509285474","title":"ImpediMed (ASX:IPD) investors are sitting on a loss of 72% if they invested three years ago","url":"https://stock-news.laohu8.com/highlight/detail?id=2509285474","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509285474?lang=en_us&edition=fundamental","pubTime":"2025-02-05 12:14","pubTimestamp":1738728899,"startTime":"0","endTime":"0","summary":"As every investor would know, not every swing hits the sweet spot. But really big losses can really drag down an overall portfolio. So take a moment to sympathize with the long term shareholders of ImpediMed Limited , who have seen the share price tank a massive 72% over a three year period. That'd be enough to cause even the strongest minds some disquiet. And the ride hasn't got any smoother in recent times over the last year, with the price 39% lower in that time.Since shareholders are down over the longer term, lets look at the underlying fundamentals over the that time and see if they've been consistent with returns.Given that ImpediMed didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. That's because fast revenue growth can be easily extrapolated to forecast profits, often of considerable size.Please","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/impedimed-asx-ipd-investors-sitting-041459915.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BK7007","BK7509","IPD.AU"],"gpt_icon":0},{"id":"2508161065","title":"The ASX medtech innovator positioned for growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2508161065","media":"LiveWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508161065?lang=en_us&edition=fundamental","pubTime":"2025-02-03 11:47","pubTimestamp":1738554461,"startTime":"0","endTime":"0","summary":"CurveBeam AI  listed on the ASX in August 2023 during a challenging period when the IPO market was firmly shut, start-ups globally had seen valuations crunched and healthcare was hard hit. CurveBeam was not immune to these market conditions, seeing its share price fall from A$0.48 per share down to lows of A$0.094.With all these positives, one may assume that CurveBeam must trade at a significant premium to its listed peers. It does not. With a market cap of just ~A$40m, CurveBeam trades at a significant discount. This valuation gap appears disconnected from the company’s robust fundamentals, including its market presence, clinical validation, and accelerating sales growth. As adoption expands, we believe the gap will narrow, offering substantial upside potential.CurveBeam AI is a medical device company on the cutting edge of orthopaedic imaging with its HiRise weight-bearing CT  system. The device addresses significa","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/the-asx-medtech-innovator-positioned-for-growth","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/the-asx-medtech-innovator-positioned-for-growth","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"livewire_stock","symbols":["LU0690374615.EUR","LU0690374961.EUR","GB00B4LPDJ14.GBP","LU1791710582.SGD","LU1983299246.USD","LU2362540622.SGD","LU2362541273.HKD","LU1791710400.SGD","BK7509","BK4082","LU2404859667.USD","LU2468319806.SGD","GB00B4QBRK32.GBP","LU2089984988.USD","BK4585","LU2362541513.USD","LU0882574055.USD","LU0528227936.USD","BK7007","IPD.AU","BK4566","BK4504","LU2404859741.USD","SYK","SFS","BK4588","CVB.AU","LU0114720955.EUR"],"gpt_icon":0},{"id":"2490792571","title":"3 ASX Penny Stocks With Market Caps Larger Than A$30M","url":"https://stock-news.laohu8.com/highlight/detail?id=2490792571","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490792571?lang=en_us&edition=fundamental","pubTime":"2024-12-09 12:08","pubTimestamp":1733717285,"startTime":"0","endTime":"0","summary":"The Australian market has recently faced challenges, with the ASX200 dipping slightly and sectors like energy and financials underperforming due to falling commodity prices and economic concerns. In such a climate, investors often seek opportunities that balance potential growth with manageable risk, making penny stocks an intriguing option. Although considered a somewhat outdated term, penny stocks still represent affordable entry points into smaller or newer companies that may offer growth potential when backed by strong financial health.Overview: ImpediMed Limited is a medical technology company that manufactures and sells bioimpedance spectroscopy  technology medical devices in the United States and Europe, with a market cap of A$109.27 million.Li-S Energy Limited, with a market cap of A$92.25 million, is pre-revenue and currently unprofitable. The company benefits from having no debt and suffi","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Nfz5wAhClXK3VMdDWSwWPw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/8e5b7feff946a5236949391477b36a92","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Nfz5wAhClXK3VMdDWSwWPw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/8e5b7feff946a5236949391477b36a92"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/3-asx-penny-stocks-market-040805476.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["LIS.AU","BK7509","BK7007","STG.AU","BK7023","BK7133","VLS.AU","BK7064","EVO.AU","MXI.AU","BK7055","BIS.AU","SHA.AU","XKO.AU","BK7062","BK7096","LBL.AU","XJO.AU","BK7132","SRV.AU","BK7088","HLO.AU","BK7070","XAO.AU","BK7129","NGI.AU","BIS","BK7114","ANG.AU","BK7077","BK7164","IPD.AU","BRI.AU"],"gpt_icon":0},{"id":"2489683446","title":"We Think ImpediMed (ASX:IPD) Needs To Drive Business Growth Carefully","url":"https://stock-news.laohu8.com/highlight/detail?id=2489683446","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489683446?lang=en_us&edition=fundamental","pubTime":"2024-12-06 07:41","pubTimestamp":1733442075,"startTime":"0","endTime":"0","summary":"Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the right price. For example, although Amazon.com made losses for many years after listing, if you had bought and held the shares since 1999, you would have made a fortune. Nonetheless, only a fool would ignore the risk that a loss making company burns through its cash too quickly.So should ImpediMed  shareholders be worried about its cash burn?For the purpose of this article, we'll define cash burn as the amount of cash the company is spending each year to fund its growth . The first step is to compare its cash burn with its cash reserves, to give us its 'cash runway'.Even though its falling revenue makes us a little nervous, we are compelled to mention that we thought ImpediMed's cash burn reduction was relatively promising. Even though we don't think it has a problem with its cash burn, the analysis","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/qrnhoA9Y9l_fYJBd0ck5WA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/983f2bdfe32b19227b1d118c45bf4f09","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/qrnhoA9Y9l_fYJBd0ck5WA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/983f2bdfe32b19227b1d118c45bf4f09"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/think-impedimed-asx-ipd-needs-234115107.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BK7007","IPD.AU","BK7509"],"gpt_icon":0},{"id":"2478984209","title":"The ASX stocks the big brokers loved and hated this week","url":"https://stock-news.laohu8.com/highlight/detail?id=2478984209","media":"LiveWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478984209?lang=en_us&edition=fundamental","pubTime":"2024-10-25 21:07","pubTimestamp":1729861637,"startTime":"0","endTime":"0","summary":"Welcome back to our weekly check-up on the biggest moves from the biggest brokers covering ASX stocks. Note this edition covers the period Thursday 17 - Thursday 24 October inclusive. Here's a quick summary of the stocks that grabbed the brokers' attention over the last week:. Bank of Queensland  posted FY24 earnings last week, and, for the most part, the big brokers liked what they saw. Top-line profit – driven by an improved second-half net interest margin  of 1.57% – was generally ahead of consensus forecasts. Management also guided to flat costs in FY25, which met with broad broker approval.However, despite plenty of price target increases for BOQ , and a big pop in its share price after the result, brokers appeared to remain circumspect about the company's outlook. The only rating upgrade came from CLSA , while most other brokers retained sell-equivalent ratings .One of the upgrading brokers, Citi, had this to say about PPT's first quarter update: \"We believe this uncertainty [pro","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/the-asx-stocks-the-big-brokers-loved-and-hated-this-week","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/the-asx-stocks-the-big-brokers-loved-and-hated-this-week","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"livewire_stock","symbols":["29M.AU","A11.AU","FLT.AU","GLN.AU","PNR","DSE","SGM.AU","MIN","PNR.AU","AMP.AU","JBH.AU","SBM","EVN.AU","WEB.AU","PPT","CYL.AU","NIM.AU","BGL.AU","EVT.AU","PPS","PYC.AU","EVN","PT","ALL","RIO.AU","DTL.AU","B4P.AU","LTM","TWE.AU","VNT.AU","JIN.AU","AAM.AU","BPT.AU","BOQ.AU","VNT","PPS.AU","SMP.AU","IPD.AU","AD8.AU","LTM.AU","NWL","NCK.AU","DUG","SBM.AU","SKO.AU","QOR.AU","AMP","BSL","SMP"],"gpt_icon":0},{"id":"2477842050","title":"BRIEF-Impedimed POsts Unaudited Revenue Of A$2.7 Million For Quarter","url":"https://stock-news.laohu8.com/highlight/detail?id=2477842050","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477842050?lang=en_us&edition=fundamental","pubTime":"2024-10-22 08:40","pubTimestamp":1729557613,"startTime":"0","endTime":"0","summary":"Oct 22 (Reuters) - ImpediMed Ltd   :   * UNAUDITED REVENUE OF A$2.7 MILLION FOR QUARTER Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IPD.AU"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":16,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IPD.AU\",params:#limit:5,,,undefined,":[{"date":"2025-04-30","symbol":"IPD.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1745971200000,"name":null,"time":"","dateTimestamp":1745935200000,"actualEps":null},{"date":"2025-01-31","symbol":"IPD.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1738278000000,"name":null,"time":"","dateTimestamp":1738242000000,"actualEps":null},{"date":"2024-10-22","symbol":"IPD.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1729551600000,"name":null,"time":"","dateTimestamp":1729515600000,"actualEps":null},{"date":"2024-08-29","symbol":"IPD.AU","type":"earning","reportTimeType":"pre","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1724889600000,"name":null,"time":"Pre-Market","dateTimestamp":1724853600000,"actualEps":null},{"date":"2024-07-29","symbol":"IPD.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1722211200000,"name":null,"time":"","dateTimestamp":1722175200000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IPD.AU\",market:\"AU\",,,undefined,":[]}}